The study aims to determine whether MZGCY inhibits inflammation in CKD rats’ kidneys and intestines by regulating the TLR4/MyD88/NF-κB signaling pathway, thereby providing a novel approach for CKD treatment. This evidence concerns the gene MYD88 and chronic kidney disease.